A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects

Abstract Biomarkers associated with asthma aetiology and exacerbation have been sought to shed light on this multifactorial disease. One candidate is the serum concentration of the Clara cell secretory protein (CC16, sometimes referred to as CC10 or uteroglobin). In this review, we examine serum CC1...

Full description

Saved in:
Bibliographic Details
Published in:Biomarkers 2007-01, Vol.12 (5), p.445-467
Main Authors: Lakind, J. S., Holgate, S. T., Ownby, D. R., Mansur, A. H., Helms, P. J., Pyatt, D., Hays, S. M.
Format: Article
Language:English
Subjects:
Animals
Asthma
Asthma - blood
Asthma - etiology
Biological and medical sciences
biomarker
Biomarkers - blood
CC10
CC16
Chronic obstructive pulmonary disease, asthma
Clara cell secretory protein
Environmental Exposure - adverse effects
Environmental Exposure - analysis
environmental exposures
Humans
Lung Diseases - blood
Lung Diseases - diagnosis
Medical sciences
Pneumology
Pneumonia - blood
Pneumonia - etiology
Uteroglobin - blood
Uteroglobin - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Biomarkers associated with asthma aetiology and exacerbation have been sought to shed light on this multifactorial disease. One candidate is the serum concentration of the Clara cell secretory protein (CC16, sometimes referred to as CC10 or uteroglobin). In this review, we examine serum CC16's relation to asthma aetiology and exacerbation. There is evidence that acute exposures to certain pulmonary irritants can cause a transient increase in serum CC16 levels, and limited evidence also suggests that a transient increase in serum CC16 levels can be caused by a localized pulmonary inflammation. Research also indicates that a transient increase in serum CC16 is not associated with measurable pulmonary damage or impairment of pulmonary function. The biological interpretation of chronic changes in serum CC16 is less clear. Changes in serum CC16 concentrations (either transient or chronic) are not specific to any one agent, disease state, or aetiology. This lack of specificity limits the use of serum CC16 as a biomarker of specific exposures. To date, many of the critical issues that must be understood before serum CC16 levels can have an application as a biomarker of effect or exposure have not been adequately addressed.
ISSN:1354-750X
1366-5804
DOI:10.1080/13547500701359327